NCT03403296View on ClinicalTrials.gov

A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)

CompletedOBSERVATIONAL

Enrollment

640

Participants

Timeline

Start Date

July 13, 2016

Primary Completion Date

July 12, 2017

Study Completion Date

July 12, 2017

Conditions

Stage II-III Gastric Cancer

Interventions

GENETIC

nProfiler I Stomach Cancer Assay Kit

qPCR by nProfiler I Stomach Cancer Assay Kit

Trial Locations (1)

03722

Department of Surgery, Yonsei University College of Medicine, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT03403296 - A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC) | Biotech Hunter | Biotech Hunter